CIPO Patents = 3

EPO Patents = 5

Forward Citations = 2

Loading Chart...

7 inventors (with patents filed for the assignee):

Harald Rau (4 out of 56 patents)

Ulrich Hersel (3 out of 40 patents)

Dirk Vetter (3 out of 21 patents)

4. Thomas Wegge (3 out of 38 patents)

5. Robert Schnepf (2 out of 7 patents)

6. Nicola Bisek (1 out of 10 patents)

7. Samuel Weisbrod (1 out of 6 patents)

8. Harald Rau (0 patent)

9. Ulrich Hersel (0 patent)

4 patents: Sort by Forward Citations

1. 11298427 - Prodrugs comprising a pyroglutamate linker (2022-04-12),

2. 9238686 - Polymeric prodrug with self-immolative linker (2016-01-19),

3. 8980242 - Aliphatic prodrug linker (2015-03-17),

4. 8450097 - Protein-proteophore complexes (2013-05-28),

Ascendis Pharma is a biopharmaceutical company focused on developing innovative therapies for rare diseases. The company's TransCon technology platform enables the creation of prodrug therapies that have the potential to improve patient outcomes and quality of life. Ascendis Pharma's pipeline includes treatments for conditions such as growth hormone deficiency and acromegaly.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

4 Patents

#355 in Palo Alto, CA

#13,660 in California

#58,991 in US

Palo Alto, CA, United States of America

Ascendis Pharma Inc.

Forward Citations = 2

7 inventors:

Harald Rau (4 out of 56 patents)

Ulrich Hersel (3 out of 40 patents)

Dirk Vetter (3 out of 21 patents)

4. Thomas Wegge (3 out of 38 patents)

5. Robert Schnepf (2 out of 7 patents)

Please report any incorrect information to support@idiyas.com

3 patents (CIPO):

Please report any incorrect information to support@idiyas.com

5 patents (EPO):

Please report any incorrect information to support@idiyas.com